JP2021528387A5 - - Google Patents

Info

Publication number
JP2021528387A5
JP2021528387A5 JP2020568796A JP2020568796A JP2021528387A5 JP 2021528387 A5 JP2021528387 A5 JP 2021528387A5 JP 2020568796 A JP2020568796 A JP 2020568796A JP 2020568796 A JP2020568796 A JP 2020568796A JP 2021528387 A5 JP2021528387 A5 JP 2021528387A5
Authority
JP
Japan
Prior art keywords
methyl
amino
pharmaceutically acceptable
benzenesulfonamide
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020568796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528387A (ja
JP7371029B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/037011 external-priority patent/WO2019241533A1/en
Publication of JP2021528387A publication Critical patent/JP2021528387A/ja
Publication of JP2021528387A5 publication Critical patent/JP2021528387A5/ja
Priority to JP2023129150A priority Critical patent/JP2023138672A/ja
Application granted granted Critical
Publication of JP7371029B2 publication Critical patent/JP7371029B2/ja
Priority to JP2025090964A priority patent/JP2025128218A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020568796A 2018-06-13 2019-06-13 ベンゼンスルホンアミド化合物および治療剤としてのその使用 Active JP7371029B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023129150A JP2023138672A (ja) 2018-06-13 2023-08-08 ベンゼンスルホンアミド化合物および治療剤としてのその使用
JP2025090964A JP2025128218A (ja) 2018-06-13 2025-05-30 ベンゼンスルホンアミド化合物および治療剤としてのその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862684436P 2018-06-13 2018-06-13
US62/684,436 2018-06-13
PCT/US2019/037011 WO2019241533A1 (en) 2018-06-13 2019-06-13 Benzenesulfonamide compounds and their use as therapeutic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023129150A Division JP2023138672A (ja) 2018-06-13 2023-08-08 ベンゼンスルホンアミド化合物および治療剤としてのその使用

Publications (3)

Publication Number Publication Date
JP2021528387A JP2021528387A (ja) 2021-10-21
JP2021528387A5 true JP2021528387A5 (enExample) 2022-06-15
JP7371029B2 JP7371029B2 (ja) 2023-10-30

Family

ID=67138087

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020568796A Active JP7371029B2 (ja) 2018-06-13 2019-06-13 ベンゼンスルホンアミド化合物および治療剤としてのその使用
JP2023129150A Withdrawn JP2023138672A (ja) 2018-06-13 2023-08-08 ベンゼンスルホンアミド化合物および治療剤としてのその使用
JP2025090964A Pending JP2025128218A (ja) 2018-06-13 2025-05-30 ベンゼンスルホンアミド化合物および治療剤としてのその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023129150A Withdrawn JP2023138672A (ja) 2018-06-13 2023-08-08 ベンゼンスルホンアミド化合物および治療剤としてのその使用
JP2025090964A Pending JP2025128218A (ja) 2018-06-13 2025-05-30 ベンゼンスルホンアミド化合物および治療剤としてのその使用

Country Status (23)

Country Link
US (2) US10745392B2 (enExample)
EP (1) EP3807281A1 (enExample)
JP (3) JP7371029B2 (enExample)
KR (1) KR102833674B1 (enExample)
CN (1) CN112262142B (enExample)
AU (1) AU2019285184B2 (enExample)
BR (1) BR112020024729A2 (enExample)
CA (1) CA3103600A1 (enExample)
CL (1) CL2020003197A1 (enExample)
CR (1) CR20200613A (enExample)
EA (1) EA202092719A1 (enExample)
EC (1) ECSP20079861A (enExample)
IL (1) IL278949B2 (enExample)
JO (1) JOP20200304A1 (enExample)
MA (1) MA52888A (enExample)
MX (1) MX2020013317A (enExample)
NI (1) NI202000098A (enExample)
PE (1) PE20211389A1 (enExample)
PH (1) PH12020552111A1 (enExample)
SA (1) SA520420768B1 (enExample)
SG (1) SG11202011862PA (enExample)
UA (1) UA127024C2 (enExample)
WO (1) WO2019241533A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20250505T1 (hr) * 2016-05-20 2025-06-20 Xenon Pharmaceuticals Inc. Spojevi benzensulfonamida i njihova uporaba za terapijska sredstva
ES2967410T3 (es) 2016-12-09 2024-04-30 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y sus usos en forma de agentes terapéuticos
CN112262142B (zh) * 2018-06-13 2023-11-14 泽农医药公司 苯磺酰胺化合物及其作为治疗剂的用途
MX2021001380A (es) 2018-08-31 2021-05-27 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos.
EP4655291A2 (en) * 2023-01-26 2025-12-03 Merck Sharp & Dohme LLC N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels background
CN117510431A (zh) * 2023-11-08 2024-02-06 浙江雅辰药物科技股份有限公司 一种异噻唑-3-酮及其衍生物、合成方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5877193A (en) 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
US6416780B1 (en) 1997-05-07 2002-07-09 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
CA2349832A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
DE19907385A1 (de) 1999-02-20 2000-08-24 Boehringer Ingelheim Pharma Neue substituierte 3-Phenoxy- und 3-Phenylalkyloxy-2-phenyl-propylamine
ES2208364T3 (es) 1999-07-16 2004-06-16 Warner-Lambert Company Llc Procedimiento para tratar dolor cronico usando inhibidores de mek.
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
JP2005162726A (ja) 2003-01-24 2005-06-23 Tanabe Seiyaku Co Ltd ピラゾロピリミジン化合物およびその製法
WO2004092123A2 (en) 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
EP1646628A1 (en) 2003-07-08 2006-04-19 Novartis AG Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
EP1673357A2 (en) 2003-08-08 2006-06-28 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
WO2006066109A2 (en) 2004-12-17 2006-06-22 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
EP1937658A1 (en) 2005-10-06 2008-07-02 Sanofi-Aventis 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
EP2316829A1 (en) 2005-12-21 2011-05-04 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2008019967A2 (en) 2006-08-15 2008-02-21 F. Hoffmann-La Roche Ag Phenyl, pyridine and quinoline derivatives
CA2666624C (en) 2006-10-19 2015-12-29 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
US8124610B2 (en) * 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
WO2009012241A1 (en) 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors
WO2009013171A2 (en) 2007-07-24 2009-01-29 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2009099177A1 (ja) 2008-02-06 2009-08-13 Taisho Pharmaceutical Co., Ltd. アミノイミダゾール誘導体
KR20110027657A (ko) 2008-06-25 2011-03-16 다이이찌 산쿄 가부시키가이샤 카르복실산 화합물
WO2010002956A2 (en) 2008-07-01 2010-01-07 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2010029300A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Bis aromatic compounds for use in the treatment of inflammation
PE20120008A1 (es) 2009-01-12 2012-01-24 Icagen Inc Derivados de fenoxi bencenosulfonamida
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
KR101541086B1 (ko) 2010-08-20 2015-08-03 허치슨 메디파르마 리미티드 피롤로피리미딘 화합물 및 그 용도
MX2014001851A (es) 2011-08-17 2014-10-24 Amgen Inc Inhibidores del canal de heteroarilo sodio.
IN2014CN02959A (enExample) 2011-10-28 2015-07-03 Merck Sharp & Dohme
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
US9630929B2 (en) * 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
SG11201408284VA (en) 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
ES2798138T3 (es) 2012-10-15 2020-12-09 Dae Woong Pharma Bloqueadores de los canales de sodio, método de preparación de los mismos y uso de los mismos
CA2889378A1 (en) 2012-10-26 2014-05-01 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
US9388179B2 (en) 2012-10-26 2016-07-12 Merck Sharp & Dohme Corp. N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
US9776995B2 (en) 2013-06-12 2017-10-03 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
JP6407285B2 (ja) 2013-09-09 2018-10-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＲＯＲγ調節因子
AU2014318979B2 (en) 2013-09-10 2019-03-28 Chromocell Corporation Sodium channel modulators for the treatment of pain and diabetes
CR20160296A (es) 2013-11-27 2016-09-20 Genentech Inc Benzamidas sustituidas y métodos para usarlas
WO2015077905A1 (en) 2013-11-29 2015-06-04 Merck Sharp & Dohme Corp. Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels
JP6337124B2 (ja) 2013-12-23 2018-06-06 パーデュー、ファーマ、リミテッド、パートナーシップ インダゾール及びその使用
CN106795149B (zh) 2015-05-05 2019-09-24 上海海雁医药科技有限公司 双环取代的苯磺酰胺衍生物、其制法与医药上的用途
EP3389654B1 (en) 2015-12-18 2023-08-16 Merck Sharp & Dohme LLC Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
US10442778B2 (en) 2016-03-22 2019-10-15 Merck Sharp & Dohme Corp. N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels
HRP20250505T1 (hr) 2016-05-20 2025-06-20 Xenon Pharmaceuticals Inc. Spojevi benzensulfonamida i njihova uporaba za terapijska sredstva
ES2897998T3 (es) 2016-10-27 2022-03-03 Bristol Myers Squibb Co Inhibidores de la acilsulfonamida del NaV1.7
US10968210B2 (en) * 2016-11-17 2021-04-06 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
ES2967410T3 (es) * 2016-12-09 2024-04-30 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y sus usos en forma de agentes terapéuticos
CN112262142B (zh) * 2018-06-13 2023-11-14 泽农医药公司 苯磺酰胺化合物及其作为治疗剂的用途
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
MX2021001380A (es) 2018-08-31 2021-05-27 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos.

Similar Documents

Publication Publication Date Title
JP2021528387A5 (enExample)
AU2011312203B2 (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
US6277875B1 (en) Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
EP2592073B1 (en) Human protein tyrosine phosphatase inhibitors and their use
US20080089859A1 (en) Administration of sleep restorative agents
TWI511728B (zh) 包含非典型抗精神病藥物及taar1激動劑之醫藥組合
AU2001271910A1 (en) Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
US20020022622A1 (en) Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging
JP2011524906A5 (enExample)
MXPA06012059A (es) Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii.
JP2004502670A5 (enExample)
JP2008538741A (ja) 鬱病の治療用及び／又は予防用の医薬組成物
JP2024509625A5 (enExample)
MXPA02003452A (es) Tratamiento de combinacion de esclerosis multiple (em), otras condiciones de desmielinacion y neuropatia periferica, especialmente neuropatias dolorosas y neuropatia diabetica.
RU2016105158A (ru) Соединения мочевины и их применение в качестве ингибиторов гидролазы амидов жирных кислот
JP2022509765A5 (enExample)
JP7430175B2 (ja) オキサジアゾールを含む化合物及びそれを含む医薬組成物
US20250186419A1 (en) Dosing regimens for treating pain
TW201105337A (en) Medicine derived from a combination of SGLT1-inhibitor and insulin sensitizer
CA2615856C (en) Use of dopamine d2/d3 receptor agonists to treat fibromyalgia
JPS6132287B2 (enExample)
RU2789456C2 (ru) Соединение, содержащее оксадиазол, и содержащая его фармацевтическая композиция
JP2023503470A5 (enExample)